Cormorant Asset Management, LP
BOSTON, MA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$1.49B2026 Q3
Positions60
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.54.8%
What Changed This Quarter?
Top Holdings
PBLS
Parabilis Medicines
10.0%
PRAX
Praxis Precision Medicines
9.8%
RAPP
Rapport Therapeutics
5.5%
EWTX
Edgewise Therapeutics
5.1%
BBOT
BridgeBio Oncology Therapeutics
4.9%
ERAS
Erasca
4.9%
BLSM
BlossomHill Therapeutics
4.5%
ANL
Adlai Nortye
4.3%
New / Increased
13 new · 1 increased
BLSMNEW
Blossomhill Therapeutics
4.5%
ETRANEW
Electra Therapeutics
2.5%
Attovia Thera…NEW
Attovia Therapeutics
2.1%
LTGONEW
Latigo Biotherapeutics
2.0%
IRDNEW
Opus Genetics
1.8%
AMLX
Amylyx Pharmaceuticals
0.6%
+50.0%
Reduced / Exited
36 reduced · 3 sold out
PRAX
Praxis Precision Medicines
9.8%
-21.9%
EWTX
Edgewise Therapeutics
5.1%
-25.9%
ABVX
Abivax
2.8%
-37.0%
DNTH
Dianthus Therapeutics
3.0%
-33.3%
BBIO
Bridgebio Pharma
1.1%
-54.5%
Damora Therap…EXIT
Damora Therapeutics
1.3%
CRNXGBPEXIT
Crinetics Pharmaceuticals In
0.2%
ALTEXIT
Altimmune
0.2%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.